MAIA Biotechnology, Inc. last reported quarterly results on Nov 7, 2023, for Q2 FY2023 (the quarter ended Sep 30, 2023). It usually reports 38–40 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 38–40 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 7, 2023
38 days after quarter end
|
Q2 FY2023
ended Sep 30, 2023
|
—
|
—
|
—
|
|
Aug 8, 2023
39 days after quarter end
|
Q1 FY2023
ended Jun 30, 2023
|
—
|
—
|
—
|
|
May 8, 2023
38 days after quarter end
|
Q4 FY2022
ended Mar 31, 2023
|
—
|
—
|
—
|
|
Nov 9, 2022
40 days after quarter end
|
Q3 FY2022
ended Sep 30, 2022
|
—
|
—
|
—
|
|
Aug 22, 2022
53 days after quarter end
|
Q2 FY2022
ended Jun 30, 2022
|
0
|
-3
|
-0.40
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MAIA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1878313
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.